{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T16:34:41Z","timestamp":1649954081868},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Virol."],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/jmv.24228","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T20:52:25Z","timestamp":1429908745000},"page":"1716-1721","source":"Crossref","is-referenced-by-count":3,"title":["A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin"],"prefix":"10.1002","volume":"87","author":[{"given":"Nowlan","family":"Selvapatt","sequence":"first","affiliation":[{"name":"Department of Hepatology; Imperial College Healthcare NHS Trust; United Kingdom"},{"name":"Department of Infection and Immunity; Imperial College Healthcare NHS Trust; United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximillian S.","family":"Habibi","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity; Imperial College Healthcare NHS Trust; United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Imperial College Healthcare NHS Trust; United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"key":"10.1002\/jmv.24228-BIB0001|jmv24228-cit-0001","doi-asserted-by":"crossref","first-page":"e15895","DOI":"10.5812\/hepatmon.15895","article-title":"Mysterious linkages between hepatitis c virus genotypes, interleukin-28b genotypes and viral clearance- a meta-analysis","volume":"14","author":"Aalaei-Andabili","year":"2014","journal-title":"Hepat Mon"},{"key":"10.1002\/jmv.24228-BIB0002|jmv24228-cit-0002","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated hcv genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Eng J Med"},{"key":"10.1002\/jmv.24228-BIB0003|jmv24228-cit-0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(99)80369-9","article-title":"Natural history of hepatitis C","volume":"31","author":"Alberti","year":"1999","journal-title":"J Hepatol"},{"key":"10.1002\/jmv.24228-BIB0004|jmv24228-cit-0004","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/liv.12127","article-title":"The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy","volume":"33","author":"Alfaleh","year":"2013","journal-title":"Liver Int"},{"key":"10.1002\/jmv.24228-BIB0005|jmv24228-cit-0005","first-page":"57","article-title":"Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin . Results from a Greek Nationwide Cohort Study","volume":"18","author":"Anagnostou","year":"2014","journal-title":"Hippokratia"},{"key":"10.1002\/jmv.24228-BIB0006|jmv24228-cit-0006","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2012","journal-title":"J Hepatol"},{"key":"10.1002\/jmv.24228-BIB0007|jmv24228-cit-0007","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.23315","article-title":"Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"51","author":"Everhart","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/jmv.24228-BIB0008|jmv24228-cit-0008","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.24228-BIB0009|jmv24228-cit-0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","article-title":"Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection","volume":"55","author":"Fried","year":"2011","journal-title":"J Hepatol"},{"key":"10.1002\/jmv.24228-BIB0010|jmv24228-cit-0010","unstructured":"2012 http:\/\/webarchive.nationalarchives.gov.uk\/20140714084352\/ http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317135237219"},{"key":"10.1002\/jmv.24228-BIB0011|jmv24228-cit-0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1478-3231.2010.02385.x","article-title":"Hepatitis C virus genotype 4 therapy: Progress and challenges","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver Int"},{"key":"10.1002\/jmv.24228-BIB0012|jmv24228-cit-0012","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.24228-BIB0013|jmv24228-cit-0013","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/jmv.24228-BIB0014|jmv24228-cit-0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jmv.20414","article-title":"Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection","volume":"77","author":"Legrand-Abravanel","year":"2005","journal-title":"J Med Virol"},{"key":"10.1002\/jmv.24228-BIB0015|jmv24228-cit-0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jmv.24069","article-title":"Hepatitis C virus genotype 4 in England: Diversity and demographic associations","volume":"87","author":"Ngui","year":"2015","journal-title":"J Med Virol"},{"key":"10.1002\/jmv.24228-BIB0016|jmv24228-cit-0016","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2893.2006.00823.x","article-title":"Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection","volume":"14","author":"Roulot","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1002\/jmv.24228-BIB0017|jmv24228-cit-0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment na\u00efve and treatment experienced patients with chronic genotype 4 HCV infection","author":"Ruane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1002\/jmv.24228-BIB0018|jmv24228-cit-0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.24228-BIB0019|jmv24228-cit-0019","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jmv.24228\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T15:05:18Z","timestamp":1625324718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24228"}},"subtitle":["A European Single Centre Experience of HCV Genotype 4"],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/jmv.24228","archive":["Portico"],"relation":{},"ISSN":["0146-6615"],"issn-type":[{"value":"0146-6615","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,24]]}}}